# A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct04955834` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04955834](<https://clinicaltrials.gov/study/NCT04955834>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04955834

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 344 participants.

## Technical summary

Registry record NCT04955834. Randomized; no masking; primary purpose treatment. Start 2021-07-27 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 344 participants (planned count; ClinicalTrials.gov record NCT04955834, source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)
- Started: 2021-07-27 (actual) (ClinicalTrials.gov record NCT04955834, source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04955834, source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04955834, source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04955834, source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04955834-2021-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin degludec injection
- Intervention (Drug): Tresiba®
- Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (`cardio:org-chia-tai-tianqing-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: 1b40fd6c7064f2eec18dfd9717ba790bf6639e60ec37d91ae2b5f216d78178af
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
